Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Daily Summary: Earnings Season Kicks Off on Wall Street Amid Mixed Sentiment
SpaceX Wants to Fly Starship Almost Every Day. Musk’s Business Empire Is Betting on It
Micron Expands Share Buybacks to $35 Billion!
US Open: Earnings season kicks off on a high note (13.10.2026)